Is COVID-19 a New Hematologic Disease?

Stem Cell Rev Rep. 2021 Feb;17(1):4-8. doi: 10.1007/s12015-020-09987-4.

Abstract

SARS-CoV-2 viruses are positive single-stranded RNA viruses, whose infection can be asymptomatic or lead to the coronavirus disease 2019 (Covid-19). Covid-19 is a respiratory infection with a significant impact on the hematopoietic system and hemostasis leading to several cardiovascular complications. Hematologic consequences of this new infection allowed medical community to start new treatment approaches concerning infection going from targeted anti-inflammatory drugs to anticoagulation or stem cell therapies. A better understanding of Covid-19 pathophysiology, in particular hematological disorders, will help to choose appropriate treatment strategies.

Keywords: Coagulopathy; Covid-19; Cytokine; D-dimers; Inflammation; Lymphopenia; Mesenchymal stem cells; SARS-CoV-2; Stem cells; Thrombosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Coagulation / genetics
  • COVID-19 / blood
  • COVID-19 / epidemiology*
  • COVID-19 / pathology
  • COVID-19 / virology
  • Cytokines / genetics
  • Hematologic Diseases / blood
  • Hematologic Diseases / epidemiology*
  • Hematologic Diseases / pathology
  • Hematologic Diseases / virology
  • Humans
  • Inflammation / blood
  • Inflammation / epidemiology
  • Inflammation / pathology
  • Inflammation / virology
  • Lymphopenia / blood
  • Lymphopenia / epidemiology
  • Lymphopenia / virology
  • Mesenchymal Stem Cells / virology
  • SARS-CoV-2 / pathogenicity*
  • Thrombosis / blood
  • Thrombosis / epidemiology*
  • Thrombosis / pathology
  • Thrombosis / virology

Substances

  • Cytokines

Grants and funding